Reply to Chhablani

Sir, We thank Dr Chhablani1 for his interest in our article2; we evaluated diffuse diabetic macular oedema and obtained good functional and anatomic results during a follow-up of 12 months after treatment with intravitreal bevacizumab, when compared with the combination of intravitreal triamcinolone and laser photocoagulation. We agree that intravitreal bevacizumab lacks in large randomized controlled trials and could be used in case of gross macular oedema in order to reduce macular thickening, followed by laser photocoagulation. The latter remains indeed the gold standard for diabetic macular oedema.